Inicio
Resultado de la búsqueda
2 búsqueda de la palabra clave 'dialysis'
Clasificado(s) por (Año de edición descendente) Refinar búsqueda Genera el flujo rss de la búsqueda
Enlace permanente de la investigación
International and multicenter real‐world study of sorafenib‐treated patients with hepatocellular carcinoma under dialysis / Juan Ignacio Marín Zuluaga
Título : International and multicenter real‐world study of sorafenib‐treated patients with hepatocellular carcinoma under dialysis Tipo de documento : documento electrónico Autores : Juan Ignacio Marín Zuluaga, Fecha de publicación : 2020 Títulos uniformes : Liver International Idioma : Inglés (eng) Palabras clave : Hepatocellular carcinoma sorafenib dialysis adverse events safety survival Resumen : Background & Aims: Information on safety and efficacy of systemic treatment in patients with hepatocellular carcinoma (HCC) under dialysis are limited due to patient exclusion from clinical trials. Thus, we aimed to evaluate the rate, prevalence, tolerability, and outcome of sorafenib in this population. Methods: We report a multicenter study comprising patients from Latin America and Europe. Patients treated with sorafenib were enrolled; demographics, dose modifications, adverse events (AEs), treatment duration, and outcome of patients undergoing dialysis were recorded. Results: As of March 2018, 6156 HCC patients were treated in 44 centres and 22 patients were concomitantly under dialysis (0.36%). The median age was 65.5 years, 40.9% had hepatitis C, 75% had Child‐Pugh A, and 85% were Barcelona Clinic Liver Cancer‐C. The median time to first dose modification, treatment duration and overall survival rate were 2.4 months (interquartile ranges [IQR], 0.8‐3.8), 10.8 months (IQR, 4.5‐16.9), and 17.5 months (95% CI, 7.2‐24.5), respectively. Seventeen patients required at least 1 dose modification. The main causes of first dose modification were asthenia/worsening of Eastern Cooperative Oncology Group‐Performance Status and diarrhoea. At the time of death or last follow‐up, four patients were still on treatment and 18 had discontinued sorafenib: 14 were due to tumour progression, 2 were sorafenib‐related, and 2 were non‐sorafenib‐related AE. Conclusions: The outcomes observed in this cohort seem comparable to those in the non‐dialysis population. Thus, to the best of our knowledge, this is the largest and most informative dataset regarding systemic treatment outcomes in HCC patients undergoing dialysis. Mención de responsabilidad : Álvaro Díaz-González, Marco Sanduzzi-Zamparelli, Leonardo G da Fonseca, Giovan G Di Costanzo, Rogerio Alves, Massimo Iavarone, Cassia Leal, Rodolfo Sacco, Ana M Matilla, Manuel Hernández-Guerra, Gabriel Aballay Soteras, Marcus-Alexander Wörns, Matthias Pinter, María Varela, Morten Ladekarl, Aline L Chagas, Beatriz Mínguez, Juan I Arenas, Alessandro Granito, Yolanda Sánchez-Torrijos, Ángela Rojas, Carlos Rodríguez de Lope, Mario R Alvares-da-Silva, Sonia Pascual, Lorenza Rimassa, José L Lledó, Carlos Huertas, Bruno Sangro, Edoardo G Giannini, Manuel Delgado, Mercedes Vergara, Christie Perelló, Alberto Lue, Margarita Sala, Adolfo Gallego, Susanna Coll, Tania Hernáez, Federico Piñero, Gustavo Pereira, Alex França, Juan Marín, Margarita Anders, Vivianne Mello, Mar Lozano, Jean C Nault, Josemaría Menéndez, Ignacio García Juárez, Jordi Bruix, María Reig Referencia : Liver Int. 2020 Jun;40(6):1467-1476. DOI (Digital Object Identifier) : 10.1111/liv.14436 PMID : 32170821 En línea : https://onlinelibrary.wiley.com/doi/epdf/10.1111/liv.14436 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5102 International and multicenter real‐world study of sorafenib‐treated patients with hepatocellular carcinoma under dialysis [documento electrónico] / Juan Ignacio Marín Zuluaga, . - 2020.
Obra : Liver International
Idioma : Inglés (eng)
Palabras clave : Hepatocellular carcinoma sorafenib dialysis adverse events safety survival Resumen : Background & Aims: Information on safety and efficacy of systemic treatment in patients with hepatocellular carcinoma (HCC) under dialysis are limited due to patient exclusion from clinical trials. Thus, we aimed to evaluate the rate, prevalence, tolerability, and outcome of sorafenib in this population. Methods: We report a multicenter study comprising patients from Latin America and Europe. Patients treated with sorafenib were enrolled; demographics, dose modifications, adverse events (AEs), treatment duration, and outcome of patients undergoing dialysis were recorded. Results: As of March 2018, 6156 HCC patients were treated in 44 centres and 22 patients were concomitantly under dialysis (0.36%). The median age was 65.5 years, 40.9% had hepatitis C, 75% had Child‐Pugh A, and 85% were Barcelona Clinic Liver Cancer‐C. The median time to first dose modification, treatment duration and overall survival rate were 2.4 months (interquartile ranges [IQR], 0.8‐3.8), 10.8 months (IQR, 4.5‐16.9), and 17.5 months (95% CI, 7.2‐24.5), respectively. Seventeen patients required at least 1 dose modification. The main causes of first dose modification were asthenia/worsening of Eastern Cooperative Oncology Group‐Performance Status and diarrhoea. At the time of death or last follow‐up, four patients were still on treatment and 18 had discontinued sorafenib: 14 were due to tumour progression, 2 were sorafenib‐related, and 2 were non‐sorafenib‐related AE. Conclusions: The outcomes observed in this cohort seem comparable to those in the non‐dialysis population. Thus, to the best of our knowledge, this is the largest and most informative dataset regarding systemic treatment outcomes in HCC patients undergoing dialysis. Mención de responsabilidad : Álvaro Díaz-González, Marco Sanduzzi-Zamparelli, Leonardo G da Fonseca, Giovan G Di Costanzo, Rogerio Alves, Massimo Iavarone, Cassia Leal, Rodolfo Sacco, Ana M Matilla, Manuel Hernández-Guerra, Gabriel Aballay Soteras, Marcus-Alexander Wörns, Matthias Pinter, María Varela, Morten Ladekarl, Aline L Chagas, Beatriz Mínguez, Juan I Arenas, Alessandro Granito, Yolanda Sánchez-Torrijos, Ángela Rojas, Carlos Rodríguez de Lope, Mario R Alvares-da-Silva, Sonia Pascual, Lorenza Rimassa, José L Lledó, Carlos Huertas, Bruno Sangro, Edoardo G Giannini, Manuel Delgado, Mercedes Vergara, Christie Perelló, Alberto Lue, Margarita Sala, Adolfo Gallego, Susanna Coll, Tania Hernáez, Federico Piñero, Gustavo Pereira, Alex França, Juan Marín, Margarita Anders, Vivianne Mello, Mar Lozano, Jean C Nault, Josemaría Menéndez, Ignacio García Juárez, Jordi Bruix, María Reig Referencia : Liver Int. 2020 Jun;40(6):1467-1476. DOI (Digital Object Identifier) : 10.1111/liv.14436 PMID : 32170821 En línea : https://onlinelibrary.wiley.com/doi/epdf/10.1111/liv.14436 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5102 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001332 AC-2020-036 Archivo digital Producción Científica Artículos científicos Disponible
Título : Uraemic neuropathy: a review Tipo de documento : documento electrónico Autores : Basilio Vagner Ramírez, ; Paula Andrea Bustamante Gómez, Fecha de publicación : 2012 Títulos uniformes : International Journal of Genetics and Molecular Biology Idioma : Inglés (eng) Palabras clave : Uraemia dialysis renal transplantation kidney failure chronic kidney disease (CKD) Resumen : Uraemic neuropathy is an increasingly common condition, it is therefore important to understand its pathophysiology as well as its clinical manifestations. The objective of this study is to make a clear diagnostic approach and to provide treatment following the patient’s condition. Mención de responsabilidad : Basilio Vagner Ramírez, and Paula Andrea Bustamante Gómez Referencia : Int Jou of Gen and Mol Bio. 2012;3(11):155–60. Derechos de uso : CC BY En línea : https://academicjournals.org/journal/IJGMB/article-abstract/A3C9FB32916 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3607 Uraemic neuropathy: a review [documento electrónico] / Basilio Vagner Ramírez, ; Paula Andrea Bustamante Gómez, . - 2012.
Obra : International Journal of Genetics and Molecular Biology
Idioma : Inglés (eng)
Palabras clave : Uraemia dialysis renal transplantation kidney failure chronic kidney disease (CKD) Resumen : Uraemic neuropathy is an increasingly common condition, it is therefore important to understand its pathophysiology as well as its clinical manifestations. The objective of this study is to make a clear diagnostic approach and to provide treatment following the patient’s condition. Mención de responsabilidad : Basilio Vagner Ramírez, and Paula Andrea Bustamante Gómez Referencia : Int Jou of Gen and Mol Bio. 2012;3(11):155–60. Derechos de uso : CC BY En línea : https://academicjournals.org/journal/IJGMB/article-abstract/A3C9FB32916 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3607 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000177 AC-2012-017 Archivo digital Producción Científica Artículos científicos Disponible Documentos electrónicos
2012-017.pdfAdobe Acrobat PDF